6/3/2023 0 Comments Foxmail error code 1![]() ![]() At the same time, a total of 0.6–1.0 μg/kg sufentanil will be administrated in three groups. Patients in the E group will receive 0.2 mg/kg etomidate within 3 min, and another 0.05 mg/kg etomidate will be administrated if the BIS value cannot achieve ≤ 60 in 3 min. Patients in the M group will receive 0.15 mg/kg midazolam within 3 min, and another 0.05 mg/kg midazolam will be employed if the BIS value cannot be ≤ 60 in 3 min. If the BIS value cannot be ≤ 60 in 3 min, then another 0.1 mg/kg remimazolam tosilate will be added in the following 2 min. So far, there is no evidence for the most appropriate sedative for cardiac surgery anesthesia.ĭuring anesthesia induction, patients in the R group will receive 0.2 mg/kg remimazolam tosilate within 3 min. However, etomidate can result in lower cortisol levels and higher adrenal insufficiency incidence compared with midazolam or propofol. Etomidate is another alternative sedative for patients with cardiovascular diseases due to its remarkably stable cardiorespiratory profile. However, midazolam has been reported to be associated with a high incidence of hypotension in patients with cardiac disease and undergoing colonoscopy. Midazolam is one of the most frequently used sedatives in cardiac anesthesia. Unlike midazolam, remimazolam has the advantages of stable hemodynamics and mild respiratory inhibition, making it a potential drug for induction in cardiac surgery anesthesia. Remimazolam is a novel and ultrashort-acting intravenous sedative-hypnotic, which mainly acts on the GABA-A receptor. ![]() However, the stability of hemodynamics of patients with VHD is difficult to maintain due to their varieties of underlying cardiac dysfunction, especially during anesthesia induction when adrenergic tone acutely declines. Timely surgical management can mitigate the deterioration to heart failure, disability, and death. Valvular heart disease (VHD) remains common in both developed and developing countries, and it keeps a major contributor to physical dysfunction and decreased quality of life. The trial sponsor has a regulatory role and will play a part in study design collection, management, analysis, and interpretation of data writing of the report and the decision to submit the report for publication Postal address: No.37 Guoxue Alley, Chengdu 610041, Sichuan, China. The trial sponsor is the West China Hospital of Sichuan University, Chengdu, China. Name and contact information for the trial sponsor Day Surgery Center, West China Hospital, Sichuan University, Chengdu 610041, China. Corresponding authorĭepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041. Liu, MDĭepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China. Yu, MDĭepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China. Li, MScĭepartment of Anesthesiology, Wu’an First People’s Hospital, Wu’an 056300, China. Liu, MScĭepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Įfficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trialĬhinese Clinical Trial Registry ID: ChiCTR2100050122, August 16, 2021ĭepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China. ![]() If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. ![]()
0 Comments
Leave a Reply. |